# XUNGENE THERAPEUTICS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xungene-therapeutics

- Industry: Healthcare IT
- Headquarters: Beijing, China
- Latest round: Angel (Sep 18, 2023)
- Investors on record: 4

## About

Founded in 2023 and based in Beijing, China, XUNGENE THERAPEUTICS is a biopharmaceutical company that focuses on the R&D of RNA small molecule drugs. It has independent intellectual property rights of RNA structure detection and artificial intelligence technology. The company was co-founded by Prof. Qiangfeng Zhang from the School of Life Sciences at Tsinghua University and Prof. Yangming Wang from the School of Future Technology at Peking University. The company has closed strategic investment in 2023 by new investor Tsinghua Holdings. In September 2023, it raised angel funding.

XUNGENE THERAPEUTICS's product is RNA small molecule drugs. The products can be used in the treatment of rare diseases and cancers. The company has built three world-leading technology platforms which are RNA structure data platform, targeted RNA small molecule high-throughput screening platform, and RNA-small molecule interaction artificial intelligence computing platform.

## Funding rounds

- Angel, Sep 18, 2023 — Cowin Capital, Beijing Capital Science and Technology Development Group Investment Management, Tsinghua Capital, Innoangel Fund

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Angel
- Beijing Capital Science and Technology Development Group Investment Management (https://capitalatlas.ai/funds/beijing-capital-science-and-technology-development-group-inv) — Angel
- Tsinghua Capital — Angel
- Innoangel Fund (https://capitalatlas.ai/funds/innoangel-fund) — Angel